In the future, risk scores could be used to tailor immunotherapy and combination treatments in clinical settings, while validating the model in prospective cohorts and exploring the mechanisms of COL5A2 and SCG2 in BLCA progression. The gene discussed is SCG2; the disease is bladder transitional cell carcinoma.